<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203313482743</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203313482743</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letters to the editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Vitamin D receptor gene polymorphism <italic>Fok I</italic> in the Polish population does not contribute to the risk of systemic lupus erythematosus</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><name><surname>Bogaczewicz</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1-0961203313482743">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Kaleta</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff2-0961203313482743">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Sysa-Jedrzejowska</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1-0961203313482743">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Robak</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1-0961203313482743">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Lukaszkiewicz</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff2-0961203313482743">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Sitkiewicz</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff2-0961203313482743">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Wozniacka</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1-0961203313482743">1</xref></contrib>
<xref ref-type="corresp" rid="corresp1-0961203313482743"/>
</contrib-group>
<aff id="aff1-0961203313482743"><label>1</label>Department of Dermatology and Venereology, Medical University of Lodz, Poland</aff>
<aff id="aff2-0961203313482743"><label>2</label>Department of Biochemistry and Clinical Chemistry, Medical University of Warsaw, Poland</aff>
<author-notes id="author-notes1-0961203313482743"><corresp id="corresp1-0961203313482743">Jaroslaw Bogaczewicz, Department of Dermatology and Venereology, Medical University of Lodz, Krzemieniecka 5, 94-017 Lodz, Poland. Email: <email>jaroslaw.bogaczewicz@umed.lodz.pl</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>7</issue>
<fpage>750</fpage>
<lpage>751</lpage>
<history>
<date date-type="received"><day>3</day><month>1</month><year>2013</year></date>
<date date-type="accepted"><day>22</day><month>2</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>Sir,</p>
<p>Recent studies have suggested that the vitamin D receptor (VDR) gene polymorphism may be involved in genetic predisposition toward susceptibility to development of autoimmune diseases such as rheumatoid arthritis.<sup><xref ref-type="bibr" rid="bibr1-0961203313482743">1</xref></sup> <italic>Fok I</italic> polymorphism is due to transition C instead of T nucleotide in a promoter region and results in greater transcriptional activity of VDR.<sup><xref ref-type="bibr" rid="bibr2-0961203313482743">2</xref></sup> Enhanced expression of the VDR gene may possibly affect the expression of other genes containing such a VDR response element, and in turn it may lead to dysregulation of the Th1/Th2 balance with subsequent greater risk of development of the autoimmune process.<sup><xref ref-type="bibr" rid="bibr1-0961203313482743">1</xref></sup> On the other hand, the VDR gene may not be responsible for the primary association with inflammation and autoimmunity but may be in linkage disequilibrium with a nearby novel disease-related locus.<sup><xref ref-type="bibr" rid="bibr1-0961203313482743">1</xref></sup> In systemic lupus erythematosus (SLE) reports concerning the role of Fok I are even more sparse than in rheumatoid arthritis. In the study by Huang et al., no essential differences in the frequency of <italic>Fok I</italic> between 52 patients with SLE and with the control group were revealed, though the patients were limited to an Asian population.<sup><xref ref-type="bibr" rid="bibr3-0961203313482743">3</xref></sup> In accordance with the latter in a recent study by Monticielo et al., no significant association was found in genotype and allelic frequencies of <italic>Fok I</italic> polymorphism between European-derived cases and controls in Brazilian patients with SLE.<sup><xref ref-type="bibr" rid="bibr4-0961203313482743">4</xref></sup> We studied 62 patients with SLE and 100 healthy individuals (<xref ref-type="table" rid="table1-0961203313482743">Table 1</xref>). Genotyping of <italic>Fok I</italic> (rs2228570) VDR polymorphism was performed by real-time polymerase chain reaction with the simple probe. The genotype frequencies in the control group were consistent with the Hardy-Weinberg equilibrium; however, in SLE they were not (χ<sup>2</sup> = 0.53; <italic>p</italic> = 0.46 and χ<sup>2</sup> = 4.14; <italic>p</italic> = 0.04, respectively). The comparison of the frequency of <italic>Fok I</italic> VDR genotypes based on the analysis with the χ<sup>2</sup> test did not reveal any essential difference between SLE patients and the control group. Our results corroborate both aforementioned studies, as the possible risk of SLE imputed to <italic>Fok I</italic> VDR gene polymorphism assessed by logistic regression analysis did not significantly differ in the group of Caucasian patients when compared to the healthy individuals. In assessing the association between VDR <italic>Fok I</italic> polymorphism and clinical and laboratory features of SLE, Monticielo et al. found no statistical significance.<sup><xref ref-type="bibr" rid="bibr4-0961203313482743">4</xref></sup> It remains in accordance with our results as no difference in the risk of development of a given clinical manifestation of SLE between genotypes of Fok I VDR gene was revealed. Several other factors such as variable sample size and ethnicity may also contribute toward contradictory results, therefore further and larger studies are required. In general, single nucleotide polymorphism in a given gene may not only lead to amino acid substitution altering protein function but also may cause altered splicing, and disruption of exonic splicing enhancer sequences or exonic mRNA stability/instability sequences.<sup><xref ref-type="bibr" rid="bibr5-0961203313482743">5</xref></sup> The VDR gene promoter directs the transcription of at least three VDR mRNA transcripts in the kidney that seem to arise from the differential splicing of 5’-noncoding exons.<sup><xref ref-type="bibr" rid="bibr2-0961203313482743">2</xref></sup> Thus VDR is regulated at both transcriptional and posttranscriptional levels.<sup><xref ref-type="bibr" rid="bibr2-0961203313482743">2</xref></sup> Alternative splicing of the retinoid receptor, thyroid hormone receptor, and other receptors is a common feature of this gene family of proteins.<sup><xref ref-type="bibr" rid="bibr1-0961203313482743">1</xref></sup> Interestingly, the VDR gene is induced with retinoic acid at a site that lies downstream of exon 1, and it is likely that this site mediates the recognition ability of induction of the transcription of VDR.<sup><xref ref-type="bibr" rid="bibr1-0961203313482743">1</xref></sup> Therefore additional studies require both genetic analysis in multiple ethnic groups and environmental influences in order to determine the overlapping and unique associations among genetic polymorphisms.<sup><xref ref-type="bibr" rid="bibr2-0961203313482743">2</xref></sup> In conclusion, in the Polish population of patients <italic>Fok I</italic> polymorphism appears not to increase the risk of SLE.
<table-wrap id="table1-0961203313482743" position="float"><label>Table 1</label><caption><p>Clinical characteristics of SLE patients according to frequency and distribution of rs2228570 <italic>Fok I</italic> VDR genotypes</p></caption>
<graphic alternate-form-of="table1-0961203313482743" xlink:href="10.1177_0961203313482743-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Signs and symptoms</th>
<th rowspan="2">Number of individuals (percentage)</th>
<th colspan="3"><italic>Fok I</italic> VDR genotypes</th>
<th rowspan="2"><italic>p<sup>a</sup></italic></th>
</tr>
<tr><th>TT</th>
<th>TC</th>
<th>CC</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Controls</td>
<td>100 (100%)</td>
<td>18 (18%)</td>
<td>53 (53%)</td>
<td>29 (29%)</td>
<td>–</td>
</tr>
<tr>
<td>SLE patients</td>
<td>62 (100%)</td>
<td>7 (11.3%)</td>
<td>38 (61.3%)</td>
<td>17 (27.4%)</td>
<td>0.44</td>
</tr>
<tr>
<td>Arthritis/arthralgia</td>
<td>49</td>
<td>5 (10.2%0</td>
<td>32 (65.31%)</td>
<td>12 (24.49%)</td>
<td>0.45</td>
</tr>
<tr>
<td>ANA titer &gt;1:160</td>
<td>48</td>
<td>5 (10.42%)</td>
<td>30 (62.5%)</td>
<td>13 (27.08%)</td>
<td>0.9</td>
</tr>
<tr>
<td>Photosensitivity</td>
<td>34</td>
<td>4 (11.76%)</td>
<td>21 (61.76%)</td>
<td>9 (26.47%)</td>
<td>0.97</td>
</tr>
<tr>
<td>Hematologic disorder</td>
<td>32</td>
<td>2 (6.25%)</td>
<td>19 (59.38%)</td>
<td>11 (34.38%)</td>
<td>0.25</td>
</tr>
<tr>
<td>Malar rash</td>
<td>28</td>
<td>4 (14.29%)</td>
<td>19 (67.86%)</td>
<td>5 (17.86%)</td>
<td>0.29</td>
</tr>
<tr>
<td>Neuropsychiatric disorder</td>
<td>12</td>
<td>2 (16.67%)</td>
<td>7 (58.33%)</td>
<td>3 (25%)</td>
<td>0.8</td>
</tr>
<tr>
<td>Renal disorder</td>
<td>8</td>
<td>1 (12.50%)</td>
<td>6 (75%)</td>
<td>1 (12.50%)</td>
<td>0.59</td>
</tr>
<tr>
<td>Oral erosions</td>
<td>6</td>
<td>1 (16.67%)</td>
<td>3 (50%)</td>
<td>2 (33.33%)</td>
<td>0.82</td>
</tr>
<tr>
<td>Serositis</td>
<td>5</td>
<td>0</td>
<td>4 (80%)</td>
<td>1 (20%)</td>
<td>0.59</td>
</tr>
<tr>
<td>Discoid rash</td>
<td>4</td>
<td>1 (25%)</td>
<td>1 (25%)</td>
<td>2 (50%)</td>
<td>0.29</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203313482743"><label>a</label>
<p>SLE patients vs. controls; SLE: systemic lupus erythematosus; VDR: vitamin D receptor; ANA: antinuclear antibody.</p></fn></table-wrap-foot>
</table-wrap></p>
</body>
<back>
<sec id="sec1-0961203313482743"><title>Funding</title>
<p>This work was supported by grant number DEC-2011/01/D/NZ5/00316 from the National Science Centre, Poland.</p>
</sec>
<sec id="sec2-0961203313482743"><title>Conflict of interest</title>
<p>None declared.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203313482743"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maalej</surname><given-names>A</given-names></name><name><surname>Petit-Teixeira</surname><given-names>E</given-names></name><name><surname>Michou</surname><given-names>L</given-names></name><name><surname>Rebai</surname><given-names>A</given-names></name><name><surname>Cornelis</surname><given-names>F</given-names></name><name><surname>Ayadi</surname><given-names>H</given-names></name></person-group>. <article-title>Association study of VDR gene with rheumatoid arthritis in the French population</article-title>. <source>Genes Immun</source> <year>2005</year>; <volume>6</volume>: <fpage>707</fpage>–<lpage>711</lpage>.</citation></ref>
<ref id="bibr2-0961203313482743"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>K</given-names></name><name><surname>Kesterson</surname><given-names>RA</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Structural organization of the human vitamin D receptor chromosomal gene and its promoter</article-title>. <source>Mol Endocrinol</source> <year>1997</year>; <volume>11</volume>: <fpage>1165</fpage>–<lpage>1179</lpage>.</citation></ref>
<ref id="bibr3-0961203313482743"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>CM</given-names></name><name><surname>Wu</surname><given-names>MC</given-names></name><name><surname>Wu</surname><given-names>JY</given-names></name><name><surname>Tsai</surname><given-names>FJ</given-names></name></person-group>. <article-title>No association of vitamin D receptor gene start codon fok 1 polymorphisms in Chinese patients with systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>2002</year>; <volume>29</volume>: <fpage>1211</fpage>–<lpage>1213</lpage>.</citation></ref>
<ref id="bibr4-0961203313482743"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Monticielo</surname><given-names>OA</given-names></name><name><surname>Brenol</surname><given-names>JC</given-names></name><name><surname>Chies</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>The role of BsmI and FokI vitamin D receptor gene polymorphisms and serum 25-hydroxyvitamin D in Brazilian patients with systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2012</year>; <volume>21</volume>: <fpage>43</fpage>–<lpage>52</lpage>.</citation></ref>
<ref id="bibr5-0961203313482743"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kutikhin</surname><given-names>AG</given-names></name></person-group>. <article-title>Impact of Toll-like receptor 4 polymorphisms on risk of cancer</article-title>. <source>Hum Immunol</source> <year>2011</year>; <volume>72</volume>: <fpage>193</fpage>–<lpage>206</lpage>.</citation></ref>
</ref-list>
</back>
</article>